Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.
Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID). Leblebicioglu H, et al. Among authors: pineda ja. Antiviral Res. 2018 Feb;150:9-14. doi: 10.1016/j.antiviral.2017.12.001. Epub 2017 Dec 5. Antiviral Res. 2018. PMID: 29217468
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Among authors: pineda ja. Antivir Ther. 2007;12(8):1225-35. Antivir Ther. 2007. PMID: 18240862
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
Macías J, del Valle J, Rivero A, Mira JA, Camacho A, Merchante N, Pérez-Camacho I, Neukam K, Rivero-Juárez A, Mata R, Torre-Cisneros J, Pineda JA; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas. Macías J, et al. Among authors: pineda ja. J Antimicrob Chemother. 2010 Oct;65(10):2204-11. doi: 10.1093/jac/dkq272. Epub 2010 Jul 22. J Antimicrob Chemother. 2010. PMID: 20656678
Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.
Merchante N, Pérez-Camacho I, Mira JA, Rivero A, Macías J, Camacho A, Gómez-Mateos J, García-Lázaro M, Torre-Cisneros J, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas. Merchante N, et al. Among authors: pineda ja. Antivir Ther. 2010;15(5):753-63. doi: 10.3851/IMP1612. Antivir Ther. 2010. PMID: 20710057
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
Neukam K, Mira JA, Gilabert I, Claro E, Vázquez MJ, Cifuentes C, García-Rey S, Merchante N, Almeida C, Macías J, Pineda JA. Neukam K, et al. Among authors: pineda ja. Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1225-32. doi: 10.1007/s10096-011-1433-5. Epub 2011 Oct 6. Eur J Clin Microbiol Infect Dis. 2012. PMID: 21971821
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA. Neukam K, et al. Among authors: pineda ja. J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13. J Hepatol. 2012. PMID: 22173157
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
Mira JA, Rivero A, de Los Santos-Gil I, López-Cortés LF, Girón-González JA, Márquez M, Merino D, del Mar Viloria M, Téllez F, Ríos-Villegas MJ, Omar M, Rivero-Juárez A, Macías J, Pineda JA; Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Mira JA, et al. Among authors: pineda ja. AIDS. 2012 Aug 24;26(13):1721-4. doi: 10.1097/QAD.0b013e3283568884. AIDS. 2012. PMID: 22695304
553 results